Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADT and Pembrolizumab in AR+ Salivary Gland Carcinoma
NCT03942653Phase 2Active, not recruiting
- Start
- May 2019
- Primary completion
- Jul 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of goserelin, pembrolizumab in salivary gland carcinoma (SGC). Started May 2019; status: active, not recruiting.
02
Drugs
goserelinpembrolizumab
03
Conditions
salivary gland carcinoma (SGC)
Beyond the preview
Go deeper on NCT03942653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03942653.